High-dose chemotherapy with autologous stem cell support in patients with breast cancer

Cancer Treatment Reviews

Volumn 24, Issue 4, 1998, Pages 249-263

  Rahman, Z U ^a   Hortobagyi, G N ^a   Buzdar, A U ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; NITROSOUREA; TAMOXIFEN; THIOTEPA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW PURGING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG TOXICITY; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PATIENT SELECTION; PROGNOSIS; TREATMENT OUTCOME;

EID: 0031768801     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90060-3     Document Type: Article

References (145)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
3. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 1990; 17: 18-32.
4. Teicher BA, Holden SA, Cucchi CA et al. Combination thiotepa and cyclophosphamide in vivo and in vitro. Cancer Res 1988; 48: 94-100.
5. Skipper HE, Schabel FM. Quantitative and cytokinetic studies in experimental tumor systems. In: Holand J, Frei E, eds, Cancer Medicine. Philadelphia, PA: Lea and Febiger, 1982: 663-684.
6. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol 1988; 121-141 (review).
7. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986; 87-94.
8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
9. Tannock IF, Boyd NF, DeBoer G et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-1387.
10. Wood WC, Budman DR, Korzun AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-1259.
11. Antman BCS, Armitage JO, Horowitz MM, Rowlings PA. Autotransplants for breast cancer in North America. Proc Annu Meet Am Soc Clin Oncol 1994; 13: A69 (meeting abstract).
12. Antman K, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
13. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
14. Damiani D, Fanin R, Silvestri F et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90: 36-42.
15. Ayash LJ, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-2992.
16. Shapiro CL, Hurd D, Clark P et al. Repetitive cycles of cyclophosphamide, thiotepa and carboplatin (CTCb) intensification with peripheral blood progenitor cells (PBPC) and filgrastim (G-CSF) in advanced breast cancer patients (pts). Proc Annu Meet Am Soc Clin Oncol 1994; 13: A67 (meeting abstract).
17. Vahdat L, Raptis G, Fennelly D et al. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1995; 1: 1267.
18. Crown J, Kritz A, Vahdat L et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11: 1144-1149.
19. Passos-Coelho J, Ross AA, Davis JM et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 1994/1998; 54: 2366-2371.
20. Ross AA, Loudovaris M, Bender JG. Immunocytochemical analysis of tumor cells in apheresis products from chemotherapy/g-csf mobilized peripheral blood and in vitro cd34 + cells from patients with metastatic breast cancer. Proc Annu Meet Am Assoc Cancer Res 1994/1998; 35: A1147 (meeting abstract).
21. Ross AA, Cooper BW, Lazarus HM et al. Different rates of detection of breast cancer cells in peripheral blood stem cell (pbsc) collections in single vs multiple specimens. Proc Annu Meet Am Soc Clin Oncol 1994/1998; 13: A60 (meeting abstract).
22. Champlin R. Purging: elimination of malignant cells from autologous blood or marrow transplants. Curr Opin Oncol 1996/1998; 8: 79-83.
23. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion 1996/ 1998; 36: 910-918.
24. Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus cd34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90: 4313-4320.
25. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral blood stem cell harvesting and cd34-positive cell selection. Cancer Treat Res 1997; 77: 143-157.
26. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC Jr. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer 1991; 68: 1272-1278.
27. Gribben JG, Nadler LM. The immunological treatment of human marrow in vitro in transplantation biology. Cancer Treat Res 1993; 64: 189-211.
28. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for b-cell lymphoma. Blood 1993; 81: 3449-3457.
29. Shpall EJ, Jones RB, Bast RC Jr et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
30. Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC. High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Ann NY Acad Sci 1995; 770: 288-304.
31. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
32. Singh B, Elfenbein GJ, Kronish LE, Perkins JB, Fields KK. Survival duration after relapse following high-dose therapy and autologous hematopoietic stem cell transplantation for high risk breast cancer patients. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A411 (meeting abstract).
33. Somlo G, Doroshow JH, Forman S et al. High-dose chemotherapy (HDCT) and stem cell rescue (SCR) for high risk breast cancer (HRBC). Update and prognostic indicators of overall (OS) and relapse-free survival (RFS). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A413 (meeting abstract).
34. Marks LB, Rosner GL, Prosnitz LR, Ross M, Vredenburgh JJ, Peters WP. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer 1994; 74: 2964-2971.
35. Holland HK, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
36. Hansen KS, Hansen LK, Larder KS. High-dose chemotherapy (HDC) with Cytoxan, thiotepa and carboplatin (Stamp V) and autologous hematopoietic stem cell transplantation (AHST) in stage II, III, and IV breast cancer: a community program experience. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A365 (meeting abstract).
37. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
38. Ellis GK, Green S, Schulman S, Tranum BL, Goldberg RS, Livingston RB. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group study. Cancer 1989; 64: 2409-2415.
39. Kalaycioglu ME, Lichtin AE, Andresen SW, Tuason L, Bolwell BJ. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1995; 18: 491-494.
40. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
41. Mulder NH, Dolsma WV, Mulder PO et al. Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. Anticancer Res 1995; 15: 1565-1568.
42. Myers SE, Mick R, Williams SF. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994; 13: 449-454.
43. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. Important Adv Oncol 1995; 215-230.
44. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
45. Rowlings PA, Antman KH, Fay JW et al. Prognostic factors for outcome of autotransplants in women with high risk primary breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A412 (meeting abstract).
46. Schwartzberg L, West W, Birch R et al. Multicenter trial of dose-escalating induction, consolidation and triple alkylator intensification in newly diagnosed metastatic breast cancer (mbc). Proc Annu Meet Am Soc Clin Oncol 1993; 12: A175 (meeting abstract).
47. Somlo G, Doroshow JH, Forman SJ et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994; 73: 125-134.
48. Somlo G, Doroshow JH, Forman SJ et al. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. Cancer 1994; 73: 1678-1685.
49. Taylor CW, List AF, Azar CA, Rifkin RM, Mosley K, Dalton WS. High dose mitoxantrone (M) thiotepa (T) and cyclophosphamide (C) plus autologous stem cell rescue (ASCR) in patients with breast cancer. Breast Cancer Treat Res 1993; 27: 183 (meeting abstract).
50. Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619-624.
51. Vincent MD, Powles TJ, Coombes RC, McElwain TJ. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 1988; 21: 255-260.
52. Wallerstein R Jr, Spitzer G, Dunphy F et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782-1788.
53. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage iv breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
54. Bitran J, Williams SF, Mick R, Gillewski T. High-dose consolidative chemotherapy with autologous hematopoietic progenitor support in the treatment of women with stage IV breast cancer: a five-year update. Exp Hematol 1992; 20: 709 (meeting abstract).
55. Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-1869.
56. Henderson IC, Berry D, Demetri GD et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node?? positive primary breast cancer. Proc Annu Meet Am Soc Clin Oncol 1998 390a:
57. Winer E, Berry D, Duggan D et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - results from CALGB 9342. Proc Annu Meet Am Soc Clin Oncol 1998; 388a.
58. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
59. Bezwoda WR, Dansey R, Seymour L. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology (Huntingt) 1989; 46: 208-211.
60. Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy (HDCT) on the outcome of patients (pt) with metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A78 (meeting abstract).
61. Peters W, Jones R, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Breast Cancer Res Treat 1996; 37: 35.
62. Peters WP, Jones RB, Vredenburgh J et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A149 (meeting abstract).
63. Rahman ZU, Frye DK, Buzdar AU et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171-3177.
64. Somlo G, Doroshow JH, Forman SJ et al. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 1997; 15: 2882-2893.
65. Peters WP, Berry D, Vredenburgh JJ et al. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving greater than or equal to 10 axillary lymph nodes (Duke/CALGB 8782). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A933 (meeting abstract).
66. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
67. Hortobagyi GN, Buzdar AU, Champlin RE et al. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer - a randomized trial. Proc Annu Meet Am Soc Clin Oncol 1998; 471a.
68. Rodenhuis S, Richel DJ, van der Wall E et al. A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Proc Annu Meet Am Soc Clin Oncol 1998; 470a.
69. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
70. Hortobagyi GN, Smith TL, Legha SSX et al. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1: 776-786.
71. Swenerton KD, Legha SS, Smith TX et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39: 1552-1562.
72. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol 1996; 14: 66-69.
73. Buzdar AU, Legha SS, Hortobagyi GN et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 1981; 47: 2798-2802.
74. Legha SS, Buzdar AU, Smith TL et al. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 1979; 91: 847-852.
75. Schwartzberg L, Birch R, Weaver C et al. Prognostic factors after high-dose chemotherapy (HDC) for high-risk stage II and III breast cancer. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A114 (meeting abstract).
76. Weaver CH, Schwartzberg LS, Greco FA et al. An intent-to-treat analysis of a multi-institution phase II trial of high-dose chemotherapy (HDC) in patients with newly diagnosed stage IV breast cancer. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A989 (meeting abstract).
77. Weaver CH, West WH, Schwartzberg LS et al. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant 1997; 19: 661-670.
78. Hu WW, Negrin RS, Stockerl-Goldstein GD et al. Factors associated with outcome for patients with stage IV breast cancer undergoing high-dose chemotherapy with hematopoietic cell support. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A344 (meeting abstract).
79. Dunphy FR, Spitzer C, Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-2167.
80. Doroshow JH, Somlo G, Ahn C et al. Prognostic factors predicting progression-free (PFS) and overall survival (OS) in patients (pts) with responsive metastatic breast cancer (MBC) treated with high-dose chemotherapy (HDCT) and bone marrow stem cell reinfusion. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A942 (meeting abstract).
81. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2045-2049.
82. Tiersten A, Raptis G, Yao TJ et al. Significant alterations in pulmonary function tests (PFT) in patients undergoing high dose chemotherapy (HDC) for breast cancer. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A917 (meeting abstract).
83. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
84. Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of interferon gamma to potentiate cyclosporin-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249-257.
85. Cluitmans FH, Esendam BH, Veenhof WF, Landegent JE, Willemze RX, Falkenburg JH. The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis. Ann Hematol 1997; 75: 27-31.
86. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIa breast cancer (greater than 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996; 2: 1509-1513.
87. Gianni L, Capri G, Mezzelani A et al. HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A491 (meeting abstract).
88. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997; 11: 43-48.
89. Seidman AD, Baselga, Yao TJ, Gilewski T, Rosen PP, Norton L. HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A80 (meeting abstract).
90. Tripathy D, Colbern GT, Kim D, Benz CC, Henderson IC, Smith HS. Enhanced doxorubicin dose responsiveness in vivo due to HER-2/neu overexpression. Breast Cancer Res Treat 1994; 32: (meeting abstract).
91. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
92. Muss H, Thor A, Kute T et al. erbB-2 (c-erbB-27; HER-2/neu) and S-phase fraction (SPF) predict response to adjuvant chemotherapy in patients (pts) with node positive (N +) breast cancer (BC): cancer and acute leukemia group B (CALGB) trial 8869. Proc Annu Meet Am Soc Clin Oncol 1993; 12: A88 (meeting abstract).
93. Wallerstein R Jr, Spitzer G, Huan S et al. Two different courses of high-dose chemotherapy with autologous marrow rescue ('tandem transplant') as intensification after conventional chemotherapy for metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 1991; 10: A149 (meeting abstract).
94. Peters WP, Ross M, Vredenburgh JJ et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25-31.
95. Ross M, Dukelow K, Gilbert C et al. Outpatient bone marrow transplantation: two year update. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A930 (meeting abstract).
96. Peters WP. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Hematologic Malignancies 1997; New Strategies and: (meeting abstract).
97. Peters WP. Advances in the supportive care of patients receiving high-dose chemotherapy and autologous bone marrow transplantation for breast cancer. Supportive Care in Cancer, 4th International Symposium, 24-27 February 1993 (meeting abstract).
98. Rahman Z, Champlin R, Rondon G et al. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 1997; 24:S17-77-S17-80.
99. Spitzer TR, Cirenza E, McAfee S et al. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 537-542.
100. Spitzer G, Dunphy FR, Petruska PJ, Velasquez WS, Adkins DR. Tandem transplants in solid rumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer. J Hematother 1993; 2: 363-365.
101. Spitzer TR, Cirenza E, Foelber R et al. High-dose cyclophosphamide (CY), carboplatin (CARBO) and autologous bone marrow (ABMT) or peripheral blood stem cell transplantation (PBSCT) for breast cancer (BC). Proc Annu Meet Am Soc Clin Oncol 1993; 12: A198 (meeting abstract).
102. Crown J, Vahdat L, Raptis G et al. Rapidly cycled courses of high-dose (HD) chemotherapy (C) supported by filgrastim (G) and peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol 1994; 13: A243 (meeting abstract).
103. Gajewski J, Rondon G, Mirza N et al. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to GF alone for hematopoieitic rescue after high-dose chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 80a (abstract).
104. Riccio L, Hudis C, Seidman A et al. Long-term distant disease-free survival (DFS) from two pilot studies of dose-dense sequential adjuvant chemotherapy (CRX) in women (pts) with resected breast cancer (BC) and more than 3 positive lymph nodes (+ LN). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A507 (meeting abstract).
105. Hudis C, Seidman A, Raptis G et al. Sequential (Seq) dose-dense (DD) doxorubicin (A)/paclitaxel (T)/cyclophosphamide (C) is less toxic than A/concurrent (Con) T + C as adjuvant therapy in resected node positive (+) breast cancer (NPBC). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A143 (meeting abstract).
106. Fennelly D, Shapiro F, Schneider J et al. A novel approach to delivery of dose-dense chemotherapy (C) in patients (pts) with advanced ovarian cancer (AOC): a phase I trial. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A921 (meeting abstract).
107. Stiff PJ, Bayer R, Tan S et al. High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trail. Clin Cancer Res 1995; 1: 1495-1502.
108. Ruvolo P, Bright E, Kennedy MJ et al. Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. Transplant Proc 1995; 27: 1363-1365.
109. Kennedy MJ, Hess AD, Passos-Coelho JL et al. Peripheral blood progenitor cell (PBPC) infusions do not inhibit the induction of autologous graft vs host disease (AGVHD) by cyclosporine A (CSA) following high-dose chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1995; 14: A915 (meeting abstract).
110. Kennedy MJ, Vogelsang GB, Beveridge RA et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
111. Stiff P, Bayer R, Sosman J, Peace D, Rad N, Kinch L. High-dose chemotherapy with marrow rescue and cyclosporin A: a combined modality approach to overcome drug resistance in solid tumors. Proc Annu Meet Am Soc Clin Oncol 1993; 12: A327 (meeting abstract).
112. Rahman Z, Kavanagh J, Giles R et al. Paclitaxel immediately following autologous bone marrow transplantation further reduces residual disease in patients with metastatic breast cancer (MBC). Proc Annu Meet Am Assoc Cancer Res 1997; 38: A165 (meeting abstract).
113. Ueno NT, Rondon G, Mirza NQ et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin Oncol 1998; 16: 986-993.
114. Garcia-Sanchez F, Pizzorno G, Cooperberg M, Krause DS, Crystal R, Deisseroth AB. Effective bone marrow purging using an adenovirus vector containing the prodrug activation unit cytosine deaminase. Proc Annu Meet Am Soc Clin Oncol 1997/1998; 16: A320 meeting abstract.
115. Chung I, Crystal RG, Schwartz P et al. Cytotoxicity of cytosine deaminase (cd) adenoviral vectors (av) with a promoter (I-plastin) for epithelial cancer cells. Effective bone marrow purging using an adenovirus vector containing the prodrug activation unit cytosine deaminase. Proc Annu Meet Am Soc Clin Oncol 1997/1998; 16:A320 (meeting abstract).
116. Chung I, Crystal RG, Schwartz P, Pizzorno G, Deisseroth AB. Chemosensitization of human ovarian carcinoma by recombinant adenoviral vector containing tumor-specific cytosine deaminase transcription unit. Proc Annu Meet Am Assoc Cancer Res 1997/1998; 38: A2549 (meeting abstract).
117. O'Shaughnessy JA, Cowan KH, Nienhuis AW et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 1994; 5: 891-911.
118. Hanania EG, Giles RE, Claxton D et al. Multiple drug resistance (MDR-1) genetic chemoprotection autologous transplants of retroviral vector mediated MDR-1 stromal transduced CD34 selected cells generate post-transplant bone marrow positive for viral MDR-1 sequences. Proc Annu Meet Am Soc Clin Oncol 1996; 15: A583 (meeting abstract).
119. Douer D, Levine A, Anderson WF et al. High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults. Hum Gene Ther 1996; 7: 669-684.
120. Dunbar CE, Bodine DM, Sorrentino B et al. Gene transfer into hematopoietic cells. Implications for cancer therapy. Ann NY Acad Sci 1994; 716: 216-224, discussion 224-7.
121. Cowan KH, O'Shaughnessy J, Schneider E et al. Transfer of drug resistance genes into human hematopoietic cells (Meeting abstract). SBT93: Society for Biological Therapy, 8th Annual Scientific Meeting: Biological Therapy of Cancer - VIII, 10-14 November 1993.
122. Hanania EG, Giles RE, Claxton D et al. Post-transplant frequency of genetically modified cells using retroviral-mediated multiple drug resistance (MDR-1) stromal transduction protocol in breast and ovarian cancers. Proc Annu Meet Am Assoc Cancer Res 1996; 37: A2363 (meeting abstract).
123. Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 1995; 2: 279-284.
124. Hanania EG, Fu S, Zu Z et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 1995; 2: 285-294.
125. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1994; 1: 21-25.
126. Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-3076.
127. Bachier C, Giles RE, Ellerson D et al. CD34+ selection and retroviral hematopoietic gene marking to determine the role of bone marrow and peripheral blood grafts on relapse in patients with follicular non-Hodgkin's lymphoma (FNHL). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A574 (meeting abstract).
128. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood 1996; 88: 1887-1894.
129. Serrano F, Varas F, Bernad A, Bueren JA. Accelerated and long-term hematopoietic engraftment in mice transplanted with ex vivo expanded bone marrow. Bone Marrow Transplant 1994; 14: 855-862.
130. Leigh BR, Webb S, Hancock SL, Knox SJ. Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice. Stem Cells 1994; 12: 430-435.
131. de Revel T, Appelbaum FR, Storb R et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795-3799.
132. Champlin RE, Mehra R, Kaye JA et al. Recombinant human interleukin eleven (rhIL-11) following autologous BMT for breast cancer. Blood 1994; 84: 395a (meeting abstract).
133. Champlin R, Mehra R, Kaye J et al. Phase I study of recombinant human interleukin-11 following autologous BMT in patients with breast cancer. Proc Annu Meet Am Soc Clin Oncol 1994; 13: A201 (meeting abstract).
134. Donato M, Korbling M, Gajewski J, Mehra R, Champlin R. Peripheral blood stem cell (PBSC) mobilization with chemotherapy and G-CSF versus G-CSF alone, with or without IL-3. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A322 (meeting abstract).
135. Champlin R, Korbling M, Donato M et al. Recombinant human thrombopoietin (rhTPO) for mobilization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer: preliminary results of a phase I trial. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A352 (meeting abstract).
136. Shapiro F, Yao TJ, Raptis G, Reich L, Norton L, Moore MA. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood 1994; 84: 3567-3574.
137. Moore MA, Schneider JG, Shapiro F, Bengala C. Ex vivo expansion of CD34+ hematopoietic progenitors. Prog Clin Biol Res 1994; 389: 217-228.
138. Purdy MH. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. Can J Oncol 1995; 5 (Suppl. 1): 63-68.
139. Silva MR, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol 1995; 23:1676-1681.
140. Williams SF, Lee WJ, Bender JG et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
141. Vogel W, Behringer D, Scheding S, Kanz L, Brugger W. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood 1996; 88: 2707-2713.
142. To LB, Haylock DN, Simmons PJ, Juttner CA. Ex vivo expansion of peripheral blood CD34+ cells and their maturation to functional end cells: an adjunct to hemopoietic stem cell transplantation. Exp Hematol 1992; 20: 753 (meeting abstract).
143. Gehling UM, Ryder JW, Hogan CJ et al. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp Hematol 1997; 25: 1125-1139.
144. Holyoake TL, Freshney MG, McNair L et al. Ex vivo expansion with stem cell factor and interleukin-11 augments both short-term recovery post-transplant and the ability to serially transplant marrow. Blood 1996; 87: 4589-4595.
145. Bernad A, Varas F, Gallego JM, Almendral JM, Eueren JA. Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells. Br J Haematol 1994; 87: 6-17.